JPRN-UMIN000006698已完成未知
oborI dual antiplatelet therapy as aPPropriate duratiON (NIPPON) - NoborI dual antiplatelet therapy as aPPropriate duratiON (NIPPON)
PO Associations for Establishment of Evidence in Interventions0 个研究点目标入组 4,598 人开始时间: 2011年12月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 4,598
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patient with cardiogenic shock. 2. Patient who needs continuous treatment of thienopyridine. 3. Patient with a history of stent thrombosis. 4. Patient who is confirmed to have an allergy or hypersensitivity to sirolimus or substance with a structure similar to biolims-A9 (ex., tacrolimus, everolimus). 5. Patient who is confirmed to have an allergy or not to have a tolerability to antiplatelet agents, anticoagulants or a contrast medium. 6. Patient who is confirmed to have an allergy or hypersensitivity to materials of Nobori biolims A-9 eluting stent. 7. Patient with a hemorrhagic predisposition or a history of coagulation abnormality. 8. Patient whose left ventricular ejection fraction (LVEF) is < 30%. 9. Patient under pregnancy (present, suspected or planned). 10. Patient who has a life expectancy of less than 12 months. 11. Patient who has an active bleeding. 12. Patient who is scheduled to undergo treatment requiring discontinuation of an antiplatelet agent. 13. Patient with a verified history of cerebral apoplexy or intracranial bleeding within 6 months before stenting. 14. Patient who is scheduled to undergo stent treatment in other lesions after the 30th day of the registration. 15. Patient who is received the follow-up observation. 16. Patient who has unprotected LMT lesion (50%>%DS). 17. Patients disqualified from participation by the investigator/sub-investigator. 18. Patient who underwent stent treatment with DES 6 months prior to the conduct of index PCI. 19. Lesions located within the saphenous venin graft (SVG). 20. Lesions with an anatomical structure of the coronary artery that is not eligible for treatment by the deployment of Nobori biolimus-A9 stent. 21. Lesions of in-stent restenosis in previously deployed DES.
研究者
相似试验
进行中（未招募）
不适用
ACUTE-PRASJPRN-jRCTs031220079Fujimoto Shigeru200
招募中
不适用
Dual-AntiPlatelet Therapy strategies FOR elective PCI in a REAL-world settingNL-OMON51842Amsterdam UMC1,462
招募中
3 期
To Compare Longterm Single versus Dual Antiplatelet Therapy In Ischemic Stroke due to atherosclerotic narrowing of blood vessel in the brain.CTRI/2022/01/039445Dr Rohit Bhatia
已完成
4 期
Dual AntiPlatelet Therapy for Stent Assisted Treatment of Cerebral Aneurysmintracranial aneurysmJPRN-UMIN000022462Kobe City Medical Center General Hospital300
招募中
不适用
OPTIMA-AF trialPatients with non-valvular Atrial Fibrillation and Ischemic Heart DiseaseNon-valvular atrial fibrillationischemic heart diseaseoral anticoagulantantiplatelet therapy.JPRN-jRCTs051190053Sakata Yasushi1,090